The Change of Original- and Generic-Targeted Antitumor Drugs under the National Centralized Drug Procurement Policy in Hohhot: An Interrupted Time-Series Analysis

IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Rihan Wu, Zhaotang Gong, Weisong Wang, Benben Zhu, Siri Guleng
{"title":"The Change of Original- and Generic-Targeted Antitumor Drugs under the National Centralized Drug Procurement Policy in Hohhot: An Interrupted Time-Series Analysis","authors":"Rihan Wu,&nbsp;Zhaotang Gong,&nbsp;Weisong Wang,&nbsp;Benben Zhu,&nbsp;Siri Guleng","doi":"10.1155/2024/6469912","DOIUrl":null,"url":null,"abstract":"<div>\n <p><i>Background</i>. This study aims to assess and explore the different effects of national centralized drug procurement (NCDP) on three targeted antitumor drugs’ use in clinical practice. <i>Materials and Methods</i>. Clinical drug volume data were collected covering 18 months before, during, and after the seventh round of the NCDP in Inner Mongolia. The interrupted time-series method was employed to estimate the net effect of policy impact. <i>Results</i>. The volume of generic afatinib (30 mg) increased by 25.78 DDDs, the expenditures decreased by 3641.14 yuan (<i>p</i> = 0.001), and the DDDc decreased by 124.35 yuan (<i>p</i> &lt; 0.001). The volume of generic afatinib (40 mg) increased by 65.19 DDDs (<i>p</i> &lt; 0.001), the expenditures increased by 1304.93 yuan (<i>p</i> &lt; 0.001), and the DDDc decreased by 120.2 yuan (<i>p</i> &lt; 0.001). The volume of generic sunitinib increased by 75.79 DDDs (<i>p</i> &lt; 0.001), the expenditures decreased by 15869.78 yuan (<i>p</i> &lt; 0.001), and the DDDc decreased by 243.28 yuan. There was no significant change trend in volume, expenditures, and DDDc of the three original-targeted drugs after NCDP intervention. <i>Conclusions</i>. After the policy intervention, generic afatinib (40 mg) successfully aligned with the objectives of NCDP by reducing drug costs and enhancing patient affordability; however, the desired outcomes were not achieved for generic afatinib (30 mg) and generic sunitinib. This discrepancy may be attributed to the inherent clinical efficacy and safety profiles of these drugs. Therefore, in implementing NCDP, it is necessary to enhance the clinical efficacy and safety of generic-targeted antitumor drugs while considering economic efficiency.</p>\n </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/6469912","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Pharmacy and Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2024/6469912","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background. This study aims to assess and explore the different effects of national centralized drug procurement (NCDP) on three targeted antitumor drugs’ use in clinical practice. Materials and Methods. Clinical drug volume data were collected covering 18 months before, during, and after the seventh round of the NCDP in Inner Mongolia. The interrupted time-series method was employed to estimate the net effect of policy impact. Results. The volume of generic afatinib (30 mg) increased by 25.78 DDDs, the expenditures decreased by 3641.14 yuan (p = 0.001), and the DDDc decreased by 124.35 yuan (p < 0.001). The volume of generic afatinib (40 mg) increased by 65.19 DDDs (p < 0.001), the expenditures increased by 1304.93 yuan (p < 0.001), and the DDDc decreased by 120.2 yuan (p < 0.001). The volume of generic sunitinib increased by 75.79 DDDs (p < 0.001), the expenditures decreased by 15869.78 yuan (p < 0.001), and the DDDc decreased by 243.28 yuan. There was no significant change trend in volume, expenditures, and DDDc of the three original-targeted drugs after NCDP intervention. Conclusions. After the policy intervention, generic afatinib (40 mg) successfully aligned with the objectives of NCDP by reducing drug costs and enhancing patient affordability; however, the desired outcomes were not achieved for generic afatinib (30 mg) and generic sunitinib. This discrepancy may be attributed to the inherent clinical efficacy and safety profiles of these drugs. Therefore, in implementing NCDP, it is necessary to enhance the clinical efficacy and safety of generic-targeted antitumor drugs while considering economic efficiency.

呼和浩特市国家药品集中采购政策下原研药和仿制药靶向抗肿瘤药物的变化:中断时间序列分析
研究背景本研究旨在评估和探讨国家药品集中采购(NCDP)对三种抗肿瘤靶向药物在临床实践中使用的不同影响。材料与方法。收集了内蒙古第七轮国家药品集中采购之前、期间和之后 18 个月的临床用药量数据。采用间断时间序列法估算政策影响的净效应。结果显示阿法替尼仿制药(30 毫克)的销量增加了 25.78 个 DDD,支出减少了 3641.14 元(p = 0.001),DDDc 减少了 124.35 元(p < 0.001)。仿制阿法替尼(40 毫克)的用量增加了 65.19 DDDs(p = 0.001),支出增加了 1304.93 元(p = 0.001),DDDc 减少了 120.2 元(p = 0.001)。仿制药舒尼替尼的用量增加了 75.79 DDDs (p < 0.001),支出减少了 15869.78 元 (p < 0.001),DDDc 减少了 243.28 元。在 NCDP 干预后,三种原目标药物的销量、支出和 DDDc 均无明显变化趋势。结论政策干预后,仿制药阿法替尼(40 mg)成功地实现了国家药品不良反应监测计划的目标,降低了药品成本,提高了患者的可负担性;然而,仿制药阿法替尼(30 mg)和仿制药舒尼替尼并没有达到预期结果。这种差异可能是由于这些药物固有的临床疗效和安全性造成的。因此,在实施国家临床开发计划时,有必要在考虑经济效益的同时,提高非专利抗肿瘤药物的临床疗效和安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.10
自引率
5.00%
发文量
226
审稿时长
6 months
期刊介绍: The Journal of Clinical Pharmacy and Therapeutics provides a forum for clinicians, pharmacists and pharmacologists to explore and report on issues of common interest. Reports and commentaries on current issues in medical and pharmaceutical practice are encouraged. Papers on evidence-based clinical practice and multidisciplinary collaborative work are particularly welcome. Regular sections in the journal include: editorials, commentaries, reviews (including systematic overviews and meta-analyses), original research and reports, and book reviews. Its scope embraces all aspects of clinical drug development and therapeutics, including: Rational therapeutics Evidence-based practice Safety, cost-effectiveness and clinical efficacy of drugs Drug interactions Clinical impact of drug formulations Pharmacogenetics Personalised, stratified and translational medicine Clinical pharmacokinetics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信